A monthly figure is designed to feel small, and the way to test that feeling is to compare it against something that is charged once. Bariatric surgery is the obvious comparator, and somebody has done the arithmetic — a harder version of the year-long sums in what a GLP-1 actually costs.
What the analysis did
Researchers took average 2023 national retail prices for these drugs, took surgical cost estimates and adjusted them for inflation, and plotted cumulative medication spending against the flat cost of each operation to find where the lines cross [1].
For some of the drugs, the crossing arrives fast: ongoing use passes the cost of gastric bypass in less than a year and sleeve gastrectomy within about nine months. An older drug in the same class, priced lowest of those compared, takes around a year and a half to become the more expensive choice.
What it costs here instead
Across the 432 injected semaglutide figures recorded on this roster, the median billed rate is $179 a month, read September 2026 — $2,148 for a year and $6,444 across three. That is the line this comparison would be drawn against for a reader buying compounded rather than branded, and it rises far more slowly than the retail one the paper used.
The authors also name two things the arithmetic cannot capture: these drugs take time to reach full effect, so cost accumulates before benefit does, and weight tends to return after stopping — which is the finding in what stopping costs. A treatment that has to continue indefinitely has no natural point at which the spending stops.
What the comparison is not
It is not a claim that the two options are equivalent. Surgery is irreversible, carries operative risk, and produces larger and more durable weight loss than any drug in this class; the drugs are reversible, carry no operative risk, and stop working when they stop. Those differences are the decision, and cost is one input to it.
The authors are explicit about their own limits too: real-world costs vary with insurance, long-term costs and comorbidities were not fully evaluated, and patient preference carries value the model cannot price. What the paper does supply is the shape of the trade — and the shape is that a recurring charge catches a one-off one faster than most people expect, which is the same arithmetic as is a GLP-1 worth what it costs and what a GLP-1 actually costs.